Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Open Angle Glaucoma: Treatment01:27

Open Angle Glaucoma: Treatment

In open-angle glaucoma, the iridocorneal angle remains open, but the trabecular meshwork becomes stiff, slowing down the outflow of aqueous humor. This causes a buildup of aqueous humor in the anterior chamber, leading to a sudden increase in intraocular pressure. The treatment for open-angle glaucoma focuses on reducing the elevated intraocular pressure by either decreasing the secretion of aqueous humor or increasing its outflow.
Drugs such as carbonic anhydrase inhibitors, α2- and...
Angle Closure Glaucoma: Treatment01:28

Angle Closure Glaucoma: Treatment

Angle-closure glaucoma, or closed-angle glaucoma, is an eye condition where the iris bulges out and blocks the iridocorneal angle, resulting in a buildup of aqueous humor and increased intraocular pressure. Immediate medical attention is necessary due to the sudden onset of symptoms. The treatment for angle-closure glaucoma includes short-term and long-term approaches. Short-term treatment involves using eye drops like pilocarpine to lower intraocular pressure by increasing aqueous humor...
Glaucoma: Overview01:25

Glaucoma: Overview

Glaucoma is an eye condition characterized by increased intraocular pressure that damages the retina and optic nerve, leading to irreversible blindness if left untreated. The human eye has various components, including the cornea, iris, pupil, lens, and optic nerve. Aqueous humor is secreted by the epithelium of the ciliary body in the posterior chamber and flows through the trabecular meshwork and canal of Schlemm, maintaining normal intraocular pressure. The trabecular meshwork and the canal...
Ophthalmic Drug Delivery Systems01:23

Ophthalmic Drug Delivery Systems

Ophthalmic drug delivery faces major limitations due to poor absorption across the corneal membrane. This process is primarily driven by diffusion and is influenced by two main factors: the physicochemical properties of the drug and tear drainage. Most ophthalmic drugs, such as pilocarpine, epinephrine, atropine, and local anesthetics, are weak bases. They are typically formulated at an acidic pH to enhance chemical stability. However, this leads to high ionization, reducing their ability to...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Effect of key baseline disease characteristics on aflibercept 8 mg dosing interval extension: A post hoc 96-week analysis of PULSAR.

Ophthalmology. Retina·2026
Same author

Six-Month Real-World Data in Macular Edema Due to Retinal Vein Occlusion Treated with Faricimab: Swiss Retina Research Network Report.

Ophthalmology and therapy·2026
Same author

Practical Challenges for the Implementation of AI-Based Image Analysis in Ophthalmology Research: Insights and Recommendations from a Swiss Multicentric Study.

Klinische Monatsblatter fur Augenheilkunde·2026
Same author

Twelve-Month Outcomes Using Aflibercept 8 mg in Treatment-Naïve and Pretreated Diabetic Macular Edema: A Swiss Retina Research Network Report.

Ophthalmology science·2026
Same author

One-Year Real-World Outcomes of Switching to Aflibercept 8 mg in Eyes with Neovascular Age-Related Macular Degeneration: A Swiss Retina Research Network Report.

Ophthalmology and therapy·2026
Same author

Correction: One-Year Outcomes of Faricimab in Treatment-Naïve Neovascular Age-Related Macular Degeneration: A Swiss Retina Research Network Report.

Ophthalmology and therapy·2026

Related Experiment Video

Updated: May 12, 2026

Obtaining Highly Purified Toxoplasma gondii Oocysts by a Discontinuous Cesium Chloride Gradient
11:17

Obtaining Highly Purified Toxoplasma gondii Oocysts by a Discontinuous Cesium Chloride Gradient

Published on: November 3, 2009

Therapy for ocular toxoplasmosis--the future.

Justus G Garweg1, Miles R Stanford

  • 1Swiss Eye Institute, University of Bern , Bern Switzerland. justus.garweg@swiss-eye-institute.com

Ocular Immunology and Inflammation
|April 27, 2013
PubMed
Summary

Current ocular toxoplasmosis treatments do not improve visual outcomes or prevent recurrences. New strategies are needed to target parasite physiology and prevent transmission.

Area of Science:

  • Ophthalmology
  • Infectious Diseases
  • Parasitology

Background:

  • Ocular toxoplasmosis treatment aims to preserve vision and minimize relapses.
  • Existing therapies show limited impact on visual outcomes and recurrence rates.
  • No current antibiotic effectively eliminates bradyzoites, the dormant parasite stage.

Purpose of the Study:

  • To review current treatment strategies for ocular toxoplasmosis.
  • To identify gaps in therapeutic approaches and areas for future development.
  • To emphasize the need for a personalized therapeutic strategy.

Main Methods:

  • Analysis of small controlled studies on ocular toxoplasmosis treatments.
  • Review of current antibiotic efficacy against bradyzoites.

More Related Videos

3-D Imaging and Analysis of Neurons Infected In Vivo with Toxoplasma gondii
06:33

3-D Imaging and Analysis of Neurons Infected In Vivo with Toxoplasma gondii

Published on: December 9, 2014

Related Experiment Videos

Last Updated: May 12, 2026

Obtaining Highly Purified Toxoplasma gondii Oocysts by a Discontinuous Cesium Chloride Gradient
11:17

Obtaining Highly Purified Toxoplasma gondii Oocysts by a Discontinuous Cesium Chloride Gradient

Published on: November 3, 2009

3-D Imaging and Analysis of Neurons Infected In Vivo with Toxoplasma gondii
06:33

3-D Imaging and Analysis of Neurons Infected In Vivo with Toxoplasma gondii

Published on: December 9, 2014

  • Evaluation of treatment recommendations based on lesion characteristics and patient status.

    • Main Results:

    • Antiparasitic treatment is recommended for specific lesion types, particularly in South American patients.
    • Systemic antibiotic therapy is crucial for immunosuppressed individuals.
    • Corticosteroid monotherapy is strongly contraindicated.
    • Prophylactic antibiotics may decrease recurrence in endemic regions and in the immunosuppressed.

    Conclusions:

    • Therapeutic decisions should consider parasite strain, lesion location, and inflammation severity.
    • Novel treatments targeting parasite physiology offer promising prospects.
    • Global public health initiatives are essential to prevent transmission and improve water safety.